TheraRadar
Data updated: May 26, 2026

ZURAGARD (isopropyl alcohol)

Trial Activity: Growth 2 active trials
Dermatology Approved 2019-04-26

Development Insights

M.D. Anderson Cancer Center conducting 1 trials (33%)
3 indications explored (Focused)
malignant neoplasm (1 trials)
prostatic cancer (1 trials)
infectious diseases (1 trials)
2
Indications
--
Phase 3 Trials
7
Years on Market

Details

Status
Over-the-counter
First Approved
2019-04-26
Patent Cliff
2036

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
TOPICAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: ISOPROPYL ALCOHOL

ZURAGARD Approval History

2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2019 to 2021 · 1 indication expansions
Jun 2021 SUPPL
Efficacy
Apr 2019 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer

What ZURAGARD Treats

2 FDA approvals

Originally approved for its first indication in 2019 . Covers 2 distinct patient populations.

  • Other (2)
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT04181463 2019-0472 NCI-2019-07377, 2019-0472 Ph 2 not yet recruiting Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer
NCT06836271 HititUrology001 Ph 2 not yet recruiting Cleaning the Biopsy Needle in TRUS Bx
NCT01361997 2011HRAEB001 Ph 3 completed Isopropyl Alcohol Against Chlorhexidine - Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ZURAGARD FDA Label Details

View full patent landscape →
5 OB patents · 2 families · 67 international docs across 17 countries

ZURAGARD Patents & Exclusivity

Latest Patent: Apr 2036

Patents (5 active)

US9844654 Expires Apr 24, 2036
US10688291 Expires Dec 20, 2034
US8389583 Expires Aug 9, 2029
US9629368 Expires May 23, 2028
US8703828 Expires May 23, 2028
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for ZURAGARD

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2036
  • 5 active patents

Trial Analysis

  • 3 total trials
  • Stage: Growth

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment